

Date: 19th July, 2018

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Tower, Dalal Street,
Fort, Mumbai - 400 001

Dear Sir/Madam,

Sub: Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its API Facility at Karakhadi

Ref.: Our earlier intimation dated 18th May, 2018 – US FDA Inspection at Alembic Pharmaceuticals API Facility at Karakhadi

We are happy to inform the exchange that the Company has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for the inspection carried out by them at our API Facility at Karakhadi during the period from 14th May, 2018 to 18th May, 2018.

With this, all our manufacturing facilities for international markets are FDA compliant.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Charandeep Singh Saluja Company Secretary



Date: 19th July, 2018

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd
'Exchange Plaza',
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 051

Dear Sir/Madam,

Sub: Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its API Facility at Karakhadi

Ref.: Our earlier intimation dated 18th May, 2018 – US FDA Inspection at Alembic Pharmaceuticals API Facility at Karakhadi

We are happy to inform the exchange that the Company has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for the inspection carried out by them at our API Facility at Karakhadi during the period from 14th May, 2018 to 18th May, 2018.

With this, all our manufacturing facilities for international markets are FDA compliant.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Charandeep Singh Saluja Company Secretary